Scynexis (SCYX) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Scynexis (SCYX) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - | -27.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.20% |
| Mar 31, 2026 | 21.43% |
| Dec 31, 2025 | 38.01% |
| Sep 30, 2025 | 33.78% |
| Jun 30, 2025 | 19.80% |
| Mar 31, 2025 | 0.37% |
| Dec 31, 2024 | 46.50% |
| Sep 30, 2024 | -66.81% |
| Jun 30, 2024 | -120.50% |
| Mar 31, 2024 | 27.81% |
| Dec 31, 2023 | 14.12% |
| Sep 30, 2023 | -57.85% |
| Jun 30, 2023 | 176.59% |
| Mar 31, 2023 | -69.13% |
| Dec 31, 2022 | -12.92% |
| Sep 30, 2022 | -55.02% |
| Jun 30, 2022 | -16.67% |
| Mar 31, 2022 | 23.51% |
| Dec 31, 2021 | -48.38% |
| Sep 30, 2021 | 61.93% |